Chlorproguanil/dapsone/artesunate (abbreviated CDA) was an experimental antimalarial treatment that entered Phase III clinical trials in 2006. Development was halted because it was associated with an increased risk of haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.